Please try another search
For the nine months ended 30 September 2016, Tetralogic Pharmaceuticals Corp revenues was not reported. Net loss decreased 25% to $26.4M. Lower net loss reflects Research & Development Expenses decrease of 75% to $4.7M (expense), Stock-based Compensation in R&D decrease of 93% to $87K (expense), General & Administrative expenses decrease of 19% to $4.4M (expense).
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -9.22 | -5.02 | -9.34 | -12.94 |
Net Income | -8.63 | -6.75 | -11.07 | -14.27 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Assets | 42.79 | 51.06 | 57.6 | 64.02 |
Total Liabilities | 73.73 | 73.31 | 73.66 | 69.96 |
Total Equity | -30.94 | -22.25 | -16.06 | -5.94 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -14.69 | -11.89 | -6.03 | -34.89 |
Cash From Investing Activities | 5.26 | 5.26 | 5.26 | 35.45 |
Cash From Financing Activities | 0 | 0 | 0 | 1.79 |
Net Change in Cash | -9.42 | -6.63 | -0.76 | 2.23 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review